From the premise that first-in-class drugs will be discovered by integrating novel, custom-designed privileged chemotypes with validated in vivo systems neurobiology assays and brain circuit imaging, Blue Oak Pharmaceuticals is structured around finding the next generation of drugs for the brain disorders. Experts in the systems neurobiology of brain disorders, medicinal chemistry and informatics, the firm's industry-leading productivity integrates a “global research team” that integrates established partners with cutting-edge technologies in behavioral profiling, synthetic chemistry and brain imaging. Their approach is to advance first-in-class clinical candidates to early phase proof-of-concept studies using translational medicine biomarkers for brain circuit activity.
